NEW YORK CITY, NY / ACCESSWIRE / November 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
Investigation Details
On August 9, 2024, Humacyte issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue-engineered vessel (ATEV) in the vascular trauma indication." On this news, Humacyte's stock price fell $1.30 per share, or 16.43%, to close at $6.61 per share on August 12, 2024. Then, on October 17, 2024, the FDA published a letter on Form 483, which had been sent to Humacyte's Chief Operating Officer on April 5, 2024, listing inspectional observations by the FDA. Specifically, the FDA observed in its Form 483 letter that the Company's facility had no microbial quality assurance, inadequate quality assurance, and reciting that under FDA regulations, its observer, in his or her judgment, indicated that the observations consisted in whole or part of filthy, putrid, or decomposed substance or has been prepared, packed or held under insanitary conditions whereby it may have been become contaminated with filth, or whereby it may have been rendered injurious to health. On this news, Humacyte's stock price fell $0.95 per share, or 16.35%, to close at $4.86 per share on October 17, 2024.
What's Next?
If you are aware of any facts relating to this investigation or purchased Humacyte securities, you can assist this investigation by visiting the firm's site: bgandg.com/HUMA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC